Brief review
The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis

https://doi.org/10.1016/1043-2760(94)90162-7Get rights and content

Abstract

Diabetes carries an increased risk of atherosclerotic disease that is not fully explained by known cardiovascular risk factors. There is accumulating evidence that advanced glycation of structural proteins, and oxidation and glycation of circulating lipoproteins, are implicated in the pathogenesis of diabetic atherosclerosis. Antioxidants can inhibit oxidation and advanced glycation in vitro, and antioxidant therapy can prevent cardiovascular disease in nondiabetic individuals. Large-scale clinical studies are required to determine the therapeutic role of antioxidants and specific antiglycation agents in diabetic vascular disease.

References (77)

  • E. Schleicher et al.

    Nonenzymatic glycosylation of human serum lipoproteins

    FEBS Lett

    (1981)
  • U. Steinbrecher

    Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products

    J Biol Chem

    (1987)
  • D.K. Yue et al.

    Abnormalities of ascorbic acid metabolism and diabetic control: differences between diabetic patients and diabetic rats

    Diabetes Res Clin Pract

    (1990)
  • Y. Aoki et al.

    Protective effect of vitamin E supplementation on increased thermal stability of collagen in diabetic rats

    Diabetologia

    (1992)
  • M.A. Austin et al.

    Low density lipoprotein subclass patterns and risk of myocardial infarction

    JAMA

    (1988)
  • M.A. Austin et al.

    Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease

    Circulation

    (1990)
  • P.A. Barnett et al.

    The effect of oxidation on sorbital pathway kinetics

    Diabetes

    (1986)
  • J.W. Baynes

    Role of oxidated stress in development of complications in diabetes

    Diabetes

    (1991)
  • J. Brett et al.

    Advanced glycosylation end products selectively attract monocytes to migrate across endothelial cell monolayers, and induce activation and growth factor elaboration [abst]

    Circulation

    (1990)
  • M. Brownlee

    Non-enzymatic glycosylation of macromolecules: prospects of pharmacologic modulation

    Diabetes

    (1992)
  • M. Brownlee et al.

    Nonenzymatic glycosylation products on collagen covalently trap low density lipoprotein

    Diabetes

    (1985)
  • M. Brownlee et al.

    Aminoguanidine prevents diabetes-induced arterial wall protein cross linking

    Science

    (1986)
  • M. Brownlee et al.

    Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

    N Engl J Med

    (1988)
  • R. Bucala et al.

    Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vaso dilation in experimental diabetes

    J Clin Invest

    (1991)
  • R. Bucala et al.

    Lipid advanced glycation: pathway for lipid oxidation in-vivo

  • A. Ceriello et al.

    Vitamin E reduction of protein glycosylation in diabetes: new prospects for the prevention of diabetic complications?

    Diabetes Care

    (1991)
  • A.S. Charonis et al.

    Structural and functional changes of laminin and type 4 collagen after non-enzymatic glycation

    Diabetes

    (1992)
  • J.A. Corbett et al.

    Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction

    Diabetes

    (1992)
  • L.K. Curtiss et al.

    A novel method for generating region specific monoclonal antibodies to modify proteins: application to the identification of human glycosylated low density lipoproteins

    J Clin Invest

    (1983)
  • L.K. Curtiss et al.

    Plasma apolipoproteins AI, AII, B, CI and E are glycosylated in hyperglycemic diabetic subjects

    Diabetes

    (1985)
  • S.J. Davie et al.

    Effect of vitamin C on glycosylation of proteins

    Diabetes

    (1992)
  • P.B. Duell et al.

    Non-enzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux

    Diabetes

    (1991)
  • W. Durante et al.

    Impairment of endothelium-dependent relaxation in aortae from spontaneously diabetic rats

    Br J Pharmacol

    (1988)
  • D. Edelstein et al.

    Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine

    Diabetes

    (1992)
  • H. Esterbauer et al.

    Vitamin E and other lipophilic antioxidants protect LDL against oxidation

    Fat Sci Technol

    (1989)
  • H. Esterbauer et al.

    Continuous monitoring of in vitro oxidation of human low density lipoprotein

    Free Radic Res Commun

    (1989)
  • M.-X. Fu et al.

    Role of oxygen in cross linking and chemical modification of collagen by glucose

    Diabetes

    (1992)
  • J. Gazziano et al.

    Beta carotene therapy for chronic stable angina [abst]

    Circulation

    (1990)
  • Cited by (19)

    • Resistance to glycation in the zebra finch: Mass spectrometry-based analysis and its perspectives for evolutionary studies of aging

      2022, Experimental Gerontology
      Citation Excerpt :

      Further reactions yield a highly heterogeneous group of advanced glycation end products (AGEs, (Poulsen et al., 2013; Ramasamy et al., 2010)). Abnormal glycation levels in humans, e.g. when glycaemia is high, promotes oxidative stress and diabetes, cardiovascular and neurodegenerative diseases, and may ultimately contribute to aging (Masoro et al., 1989; O'Brien and Timmins, 1994; Sell et al., 1996; Semba et al., 2010; Ulrich and Cerami, 2001). Recent hypotheses put forward to explain the bird paradox “high glucose – low glycation – long lifespan” included a lower propensity to accumulate AGEs over time (Klandorf et al., 1999; Rattiste et al., 2015), a lower permeability to glucose and/or a shorter half-life of certain cell types that are sensitive to AGEs accumulation (i.e. red blood cells) or specificities of avian protein sequences that may limit potential for Amadori reactions (Holmes et al., 2001; Zuck et al., 2017).

    • Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta

      2017, Atherosclerosis
      Citation Excerpt :

      First, the diabetic arterial wall is characterized by increased expression of extracellular proteoglycans, as well as the accumulation of glycated proteins, which may mediate LDL retention [30]. Second, prolonged hyperglycaemia is associated with excessive cross-linking of collagen and ECM proteins in the vascular wall, resulting mainly from glycation of proteins and formation of advanced glycation end products (AGEs), which could lead to both accumulation and subsequent oxidative modification of LDL [31,32]. Third, changes in LDL retention could lead to changes in the distribution of atherosclerosis.

    • Diabetes status modifies the association between carotid intima-media thickness and incident heart failure: The Atherosclerosis Risk in Communities study

      2017, Diabetes Research and Clinical Practice
      Citation Excerpt :

      Carotid IMT may have been increased in persons with abnormal glucose metabolism, compared to those with a NFG, for a number of reasons including a direct effect of chronic hyperglycaemia on the carotid artery walls or an indirect effect of diabetes-related metabolic abnormalities. Chronic hyperglycaemia, advanced glycosylation end-products [21,22], and the acceleration of lipoprotein oxidation [23], might increase the risk of carotid atherosclerosis in these individuals. In addition, T2D is also associated with CHD risk factors, including dyslipidaemia and hypertension [20], both of which have been linked to greater CIMT.

    • In vitro and in vivo antioxidant properties of gliclazide

      2000, Journal of Diabetes and its Complications
    View all citing articles on Scopus
    View full text